Anti-CD20 monoclonal antibody that depletes CD20+ B cells via antibody-dependent cellular cytotoxicity and complement.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes them via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and phagocytosis.
Rituximab binds CD20 and triggers Fc-mediated immune killing: NK-cell ADCC, complement-dependent cytotoxicity (MAC formation), and macrophage phagocytosis of CD20+ cells.
Autologous T cells genetically engineered to express an anti-CD20 chimeric antigen receptor, redirecting T cells to recognize CD20 on malignant B cells and induce TCR-independent activation, cytokine release, cytotoxic killing, and in vivo expansion.
Autologous T cells are genetically engineered to express an anti-CD20 chimeric antigen receptor that recognizes CD20 on malignant B cells and triggers TCR-independent activation through CAR signaling, leading to cytokine release, proliferation, and targeted cytotoxic killing of CD20-positive cells.
Anti-CD20 CAR engagement activates the infused T cells to kill CD20+ cells via perforin/granzyme-mediated cytolysis and apoptosis (± Fas/FasL), with associated cytokine release.
Autologous T cells engineered to express an anti-CD19 chimeric antigen receptor targeting CD19-positive B-cell malignancies, mediating TCR-independent activation, cytokine release, cytotoxicity, and in vivo expansion.
Autologous T cells are genetically engineered to express an anti-CD19 chimeric antigen receptor. Upon binding CD19 on malignant B cells, the CAR provides TCR/MHC-independent activation signals that trigger T-cell activation, cytokine release, proliferation, and cytotoxic killing of CD19-positive tumor cells.
CD19-directed CAR-T cells bind CD19 and, upon activation, kill target cells via perforin/granzyme-mediated cytolysis and death-receptor pathways (e.g., Fas/FasL).
Human IgG1 monoclonal antibody immune checkpoint inhibitor targeting PD-L1; blocks PD-L1 interaction with PD-1/B7.1 to restore cytotoxic T-cell activity and can mediate ADCC.
Human IgG1 monoclonal antibody that binds PD-L1, blocking its interaction with PD-1 and B7.1 to lift inhibitory signaling and restore cytotoxic T-cell activity; its Fc region can mediate antibody-dependent cellular cytotoxicity (ADCC) against PD-L1–expressing tumor cells.
Avelumab binds PD-L1 on target cells and its IgG1 Fc engages Fc gamma receptors on NK cells to trigger antibody-dependent cellular cytotoxicity (ADCC), directly killing PD-L1-expressing cells; it also blocks PD-L1/PD-1 to restore CTL killing (indirect).
Intravenous chimeric anti‑CD20 monoclonal antibody that depletes CD20+ B cells via antibody‑dependent cellular cytotoxicity, complement activation, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes them via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis.
Binds CD20 on B cells and recruits immune effectors to kill via Fc-mediated ADCC and complement-dependent cytotoxicity; can also induce apoptosis upon CD20 cross-linking.